Dirk Hasenclever

Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks.

D. Hasenclever, M. Sextro, Dirk Hasenclever, 1996, Bone marrow transplantation.

Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone.

N. Willich, S. Sehlen, V. Diehl, 1996, International journal of radiation oncology, biology, physics.

Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group

B. Burkhardt, D. Hasenclever, A. Feller, 2015, Klinische Pädiatrie.

Importance of F18-Fluorodeoxy-D-2-Glucose Positron Emission Tomography (FDG-PET) for Staging and Therapy Control of Hodgkin’s Lymphoma in Childhood and Adolescence – Consequences for the GPOH-HD 2003 Protocol

D. Hasenclever, O. Sabri, R. Kluge, 2003, Oncology Research and Treatment.

Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation

N. Schmitz, D. Hasenclever, A. Nagler, 1998, Bone Marrow Transplantation.

Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.

D. Hasenclever, E. Steiner, A. Puhl, 2008, Gynecologic oncology.

Genomic and epigenomic co-evolution in follicular lymphomas

M. Rosolowski, M. Szczepanowski, H. Trautmann, 2014, Leukemia.

High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML)

D. Hasenclever, D. Niederwieser, R. Krahl, 2002, Leukemia.